– USA, NC – Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Darlene Deptula–Hicks to its board of directors as chair of the audit committee.
“I am delighted to welcome Darlene to our board of directors,” said CEO, Steve Thornton. “She is a seasoned financial executive who brings decades of experience in business development and corporate finance having worked with both private and public life science companies. We look forward to her strategic operational and financial guidance as we advance AER-901, our drug-device combination product candidate inhaled imatinib for the treatment of pulmonary arterial hypertension which is currently in a Phase 1 trial.”
About Darlene Deptula-Hicks
Ms. Deptula-Hicks’ biopharmaceutical industry experience spans more than 30 years and includes serving in finance executive leadership positions and on the board of directors. She’s served as CFO of F-star Therapeutics, Inc. (NASDAQ: FSTX) since May 2019 and operated Crimson Consulting LLC, a strategic and financial consulting services company, since January 2018. Before that, she served as acting CFO for Northern Biologics, Inc. Ms. Deptula-Hicks has previously served in several senior executive positions including as SVP and CFO of T2 Biosystems, Inc., Senior Vice President and CFO of Pieris Pharmaceuticals, Inc., and as VP and CFO of Microline Surgical, Inc. She currently serves on the board of directors of Abcuro, Inc. and previously served on the board of directors of Giner Life Sciences, and on the board of directors and as audit committee chair of Xentic Biosciences, US Falcon, Inc., Technest Holdings, Inc., and IMCOR Pharmaceuticals.
Ms. Deptula-Hicks commented, “I am honored to join the Aerami Therapeutics board of directors at this exciting time of growth and look forward to working with the board and management team as we advance inhaled therapies to significantly improve the quality of life for people with severe respiratory and chronic diseases.”
Ms. Deptula-Hicks received an M.B.A. from Rivier University and a B.S. in Accounting from Southern New Hampshire University.
About Aerami Therapeutics
Aerami Therapeutics is a clinical-stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and chronic diseases. The Company’s lead development program is AER-901, a drug-device combination product candidate, inhaled imatinib for the treatment of pulmonary arterial hypertension currently in Phase1. It has been developed as a nebulized formulation to improve drug uptake and dosing consistency. AER-901 is designed to deliver consistent, therapeutically effective, and well-tolerated levels of imatinib through once-a-day inhalation via the Fox device, licensed from Vectura Group plc, which is both 510k cleared and CE marked.
For more information: https://aerami.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
